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Purpose: Aim was to stratify the knee MRIs of the Foundation for National Institutes of Health Osteo-
arthritis Biomarkers Consortium (FNIH) cohort into distinct structural phenotypes based on semi-
quantitative assessment and to determine risk for pain and structural progression over 48 months.
Methods: The study sample from the FNIH project was selected as a nested caseecontrol study with
knees showing either 1) radiographic and pain progression (i.e., “composite” cases), 2) radiographic
progression only (“JSL”), 3) pain progression only, and 4) neither radiographic nor pain progression. MRI
was performed on 3T systems. MRIs were read according to the MOAKS scoring system. Knees were
stratified into subchondral bone, cartilage/meniscus and inflammatory phenotypes using the baseline
visits. The relation of each phenotype to risk of being in the combined JSL plus composite outcome or
composite case only group compared to those not having that phenotype was determined using logistic
regression. Only KL2 and 3 and those without root tears were included.
Results: 485 knees were included. 362 (75%) did not have any phenotype, while 95 (20%) had the bone
phenotype, 22 (5%) the cartilage/meniscus phenotype and 19 (4%) the inflammatory phenotype. The
bone phenotype was associated with a higher odds of the combined JSL plus composite outcome and
composite outcome only (OR 1.81; [95%CI 1.14,2.85] and 1.65; 95%CI [1.04,2.61]) while the inflammatory
(OR 0.96 [95%CI 0.38,2.42] and 1.25; 95%CI [0.48,3.25]) and the cartilage/meniscus phenotypes were not
significantly associated with outcome (OR 1.30 95%CI [0.55,3.07] and 0.99; 95%CI [0.40,2,49]).
Conclusions: The bone phenotype was associated with increased risk of having both radiographic and
pain progression. Phenotypic stratification may be useful to consider when selecting patients for in-
clusion in clinical trials.
© 2020 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.F.W. Roemer, Department of
iliansplatz 3, 91054, Erlangen,
68.
gen.de, froemer@bu.edu
ternational. Published by ElsevierIntroduction
Imaging plays an important role in defining structural disease
severity and potential suitability of patients recruited to disease-
modifying osteoarthritis drug (DMOAD) trials. From a structural
perspective, it is knees with KellgreneLawrence (K-L) grades 2 and
3 that are commonly considered eligible for inclusion1. Acknowl-
edging the heterogeneity of knee OA, several phenotypes orLtd. All rights reserved.
F.W. Roemer et al. / Osteoarthritis and Cartilage 28 (2020) 1220e1228 1221subpopulations in OA that are characterized by distinct clinical
manifestations of disease have been suggested, based on certain
laboratory parameters, biochemical markers, and/or imaging find-
ings2. While magnetic resonance imaging (MRI)-based phenotypic
characterization of large cohort or clinical trial data is not available
to date, three main structural phenotypes in knee OA have been
proposed, i.e., inflammation, cartilage/meniscus and subchondral
bone3. These may progress differently and may represent distinct
tissue targets for DMOAD approaches.
Recently, Rapid OsteoArthritis MRI Eligibility Score (ROAMES)
system has been introduced that allows phenotypic stratification
based on abbreviated MRI assessment and thus, may potentially be
applicable in screening efforts for inclusion into clinical DMOAD
trials4. However, phenotypic stratification will be particularly
relevant if rates of structural or clinical progression differ between
those showing a distinct structural phenotype vs those who do not
exhibit that phenotype5.
Our aimwas to stratify the Foundation for National Institutes of
Health (FNIH) Osteoarthritis Biomarkers Consortium cohort, a well-
defined subsample of the larger Osteoarthritis Initiative (OAI) study
comparable to a clinical trial population, into distinct structural
phenotypes based on semiquantitative MRI assessment at baseline
and to determine their risk for structural progression only and both,
structural and pain progression combined over 48 months.
Methods
Sample selection
The FNIH Osteoarthritis Biomarkers Consortium study is a nes-
ted caseecontrol study embedded within the larger OAI study6. In
brief, the OAI is a multicenter prospective observational cohort
study of knee OA (https://oai.nih.gov) that enrolled 4,796 partici-
pants aged 45e79 years at four clinical centers. Details of the OAI
inclusionary and exclusionary criteria have been published7.
Case-control selection
For the nested caseecontrol study, a predetermined number of
index knees was selected in the following outcome groups: 1) case
knees had both radiographic and pain progression (i.e., “composite
cases”); control knees did not have this combination, and included 2)
knees with radiographic but not pain progression (joint space loss -
“JSL-group”), 3) knees with pain progression but not radiographic
progression, and 4) knees with neither radiographic nor pain pro-
gression. Radiographic progression was defined by a decrease in
minimal joint space width of 0.7 mm in the medial tibio-femoral
compartment from baseline to 24, 36 or 48 months. Knee pain was
assessed using the Western Ontario McMasters (WOMAC) pain sub-
scale. Symptomatic progression was defined as a persistent (2 time
points) increase of 9 points on a 0e100 normalized WOMAC score
from baseline to 24, 36, 48 or 60 months. This difference has been
documented to be clinically relevant8. The sample size for cases and
these three control groups was 194, 103, 103 and 200 knees, respec-
tively6. Knees were frequencymatched on baseline BMI category and
KL Grade. The specifics of the subject selection have been described in
detail and are available at: https://oai.epi-ucsf.org/datarelease/docs/
FNIH/OaBioFnihDataOverview.pdf.
Knee MRI acquisition
MRI of both knees was performed on identical 3T systems
(Siemens Trio, Erlangen, Germany) at the four OAI clinical sites. MRIs
were acquiredwith a dedicated quadrature transmit/receive knee coil
including a coronal intermediate-weighted (IW) two-dimensional(2D) turbo spin-echo, a sagittal three-dimensional (3D) dual echo at
steady state (DESS) sequence with additional coronal and axial ref-
ormations, and a sagittal IW fat-suppressed turbo spin-echo
sequence. Additional parameters of the full OAI pulse sequence pro-
tocol and the sequence parameters have been published in detail9.
Two musculoskeletal radiologists with 18 (FWR) and 21 (AG)
years’ experience of semi-quantitative assessment of knee OA,
blinded to clinical data and caseecontrol status, read the baseline
MRIs according to the MRI Osteoarthritis Knee Score (MOAKS)
system10. The following joint structures were assessed: cartilage
morphology, subchondral bone marrow lesions (BMLs), meniscal
status, meniscal extrusion, Hoffa-synovitis and effusion-synovitis.
Phenotypic definitions used
Based on semi-quantitative readings knees were stratified ac-
cording to the following phenotypic definitions as suggested pre-
viously4: (1) Inflammatory: Maximum grade of Hoffa- or effusion-
synovitis 2 or 3 AND sum of both features of 5 or 6 OR Effusion-
synovitis being 3 and Hoffa synovitis being 0 or 1; (2) Cartilage/
meniscus: Presence of a meniscus score of any type of meniscal
substance loss/maceration in the medial and/or lateral compart-
ment and any type of tear in the other compartment, together with
presence of ipsi-compartmental cartilage damage grades 2.1 (in
the compartment with substance loss/maceration); (3) Sub-
chondral bone: Maximum subregional BML size of grade 3 in at
least one of three knee compartments. Image examples of these
phenotypes are presented in Fig. 1. A secondary, less stringent
definition for the inflammatory (1) and the cartilage/meniscus
phenotype (2) was used for sensitivity analyses: (1) any effusion-
synovitis  2; (2) any type of meniscal substance loss/maceration
regardless of other compartment AND presence of ipsi-compart-
mental cartilage damage grades  2.1.
Analytic approach
Knees with KL 1 at baseline were excluded as these are not
considered to have radiographic OA in a clinical trial context and
would not be typically eligible for trials. Knees with posterior
meniscal root tears at baseline were also excluded as these knees
are considered at increased risk for structural progression and joint
collapse and would therefore not be suitable candidates for clinical
trials11,12. As the focus of this analysis was structure, our primary
outcome was the combined JSL plus composite outcome group
(defined as those with JSL only but not pain progression plus those
with both JSL and pain progression) with the composite case only
group (only those knees with both, pain and structural progression)
being the secondary focus. Although DMOAD clinical trials use a
combination of structural and clinical outcomes, for comprehensive
presentation of the sample and its outcomes we also present the
pain outcome only combined with the pain and structural pro-
gression outcome. We evaluated the relation of each phenotype
(using both definitions, primary and secondary for sensitivity an-
alyses) to odds of being in either the JSL or the composite case
progression group compared with those not exhibiting that
phenotype using logistic regression. We grouped phenotypes in
two ways: first evaluating the odds of progression for those with
the phenotype vs without, and then creating a three level grouping
of 1) having the phenotype, 2) having a different phenotype, 3)
having no phenotype. We ran both unadjusted models and models
adjusted for sex, race, and baseline age, BMI, K/L grade, WOMAC
pain score, use of pain medication, and JSW. We obtained P-values
and odds ratios with 95% confidence intervals from the logistic
regression models. All analyses were conducted in SAS 9.4 (SAS
Institute, Cary NC).
Fig. 1
Image examples of the different structural phenotypes according to the primary definition. A. Inflammatory
phenotype. Axial dual echo at steady-state (DESS) MRI shows marked intraarticular joint effusion dis-
tending the joint capsule consistent with grade 3 effusion-synovitis according to MOAKS (asterisk). In
addition, there is superficial cartilage damage at the medial patella facet. B. Sagittal intermediate-weighted
fat-suppressed MRI of the same knee shows diffuse hyperintensity within Hoffa's fat pad (grade 3 according
the MOAKS scoring system), a commonly used imaging surrogate on non contrast-enhanced sequences
for whole joint synovitis (arrows). The combination of these MRI findings of joint effusion and Hoffa-sy-
novitis fulfills the criteria for the inflammatory phenotype on MRI. C. Cartilage/meniscus phenotye. Coronal
intermediate-weighted MRI shows diffuse cartilage loss at the medial femur and corresponding tibia (long
arrows). In addition there is substance loss at the free edge of the meniscal body (short arrow) and marked
meniscal extrusion beyond the medial joint line (arrowhead). Diffuse meniscal damage predisposes the joint
for rapid cartilage loss. In addition, there is a horizontal-oblique tear at the posterior horn of the laterla
meniscus (not shown). Findings of bilateral meniscal damage and full thickness cartilage loss fulfill definition
of the cartilage/meniscus phenotype.D. Subchondral bone phenotype. Sagittal intermediate-weighted fat-
suppressed MRI shows a large (Grade 3) subchondral bone marrow lesion in the medial femur (arrows)
characterizing this knee as having the subchondral bone phenotype. In addition there is a focal full
thickness cartilage lesion at the central subregion of the medial femur (arrowhead).
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After exclusion of KL 1 knees (n ¼ 71) and knees with posterior
meniscal root tears (n ¼ 44), 485 knees were included. Excluded
participants were similar to included participants with respect to
baseline characteristics and case status (20% of composite casesexcluded vs 19% of controls). Mean age of the participants was 61
years (SD ± 8.8), 59 % of the participants were women, average BMI
was 31.0 kg/m2 (SD ± 4.8). 297 knees were KL 2 and 188 knees KL 3.
According to the primary definitions, 362 (75%) did not fulfil criteria
for any phenotype, while 95 (20%) had the bone phenotype, 22 (5%)
the cartilage/meniscus phenotype and 19 (4%) the inflammatory
F.W. Roemer et al. / Osteoarthritis and Cartilage 28 (2020) 1220e1228 1223phenotype. 111 (23%) had one phenotype, 11 (2%) knees had two
phenotypes and one knee had three phenotypes. When applying
the less stringent secondary definitions these numbers were 274
(56%) not fulfilling definition of any phenotype, 95 (20%) with bone,
104 (21%) with cartilage/meniscus, and 102 (21%) with inflamma-
tory phenotypes. A detailed overview of the phenotypic distribu-
tion using both definitions for the included KL 2 and 3 knees is
presented in Appendix Ia, while Appendix Ib gives details regarding
age, sex and BMI distributions for the different phenotypes.
Results of logistic regression were similar in unadjusted and
adjusted models, here we present unadjusted results. Regarding
the combined JSL plus composite outcome and the primary
phenotype definition, the bone phenotype was associated with a
higher odds of the outcome (OR 1.81; [95% CI 1.14, 2.85]) while the
inflammatory and cartilage/meniscus phenotypes were not signif-
icantly associated with the outcome (OR 0.96 [95% CI 0.38, 2.42]
and 1.30 [0.55, 3.07]) compared with those that did not fulfill the
definition for that phenotype. Having any one phenotype (vs. none)
increased odds for JSL by 1.97 times [95% CI 1.28, 3.05]. Table I
provides a detailed overview of these results. Regarding the com-
posite case outcome only and according to the primary phenotype
definition, the bone phenotype was also associated with increased
odds for having that outcome (i.e., having both structural and pain
progression) at follow-up compared with not fulfilling that
phenotype definition (OR 1.65, 95% CI [1.04, 2.61]), while the in-
flammatory and cartilage/meniscus phenotypes were not (OR 1.25,
95% CI [0.48, 3.25] and 0.99, 95% CI [0.40, 2.49]). Having any oneJSL Case
No Yes OR (95% CI)
Inflammatory Phenotype
No 241 (52%) 225 (48%) REF
Yes 10 (53%) 9 (47%) 0.96 (0.38, 2.42)
Bone Phenotype
No 213 (55%) 177 (45%) REF
Yes 38 (40%) 57 (60%) *1.81 (1.14, 2.85)
Cartilage/meniscus Phenotype
No 241 (52%) 222 (48%) REF
Yes 10 (45%) 12 (55%) 1.30 (0.55, 3.07)
Number of Phenotypes
0 201 (56%) 161 (44%) REF
1 43 (39%) 68 (61%) *1.97 (1.28, 3.05)
2þ 7 (58%) 5 (42%) 0.89 (0.28, 2.86)
Inflammatory Phenotype Group
No Phenotype 201 (56%) 161 (44%) REF
Inflammatory Phenotype 10 (53%) 9 (47%) 1.12 (0.45, 2.83)
Other Phenotype 40 (38%) 64 (62%) *2.00 (1.28, 3.12)
Bone Phenotype Group
No Phenotype 201 (56%) 161 (44%) REF
Bone Phenotype 38 (40%) 57 (60%) *1.87 (1.18, 2.97)
Other Phenotype 12 (43%) 16 (57%) 1.66 (0.77, 3.62)
Cartilage/meniscus Phenotype Group
No Phenotype 201 (56%) 161 (44%) REF
Cartilage/meniscus Phenotype 10 (45%) 12 (55%) 1.50 (0.63, 3.56)
Other Phenotype 40 (40%) 61 (60%) *1.90 (1.21, 2.98)
*statistically significant at P < 0.05.
OR eodds ratio; CI econfidence interval; JSL e joint space loss (i.e., combined JSL
plus composite outcome group, defined as those with JSL only but not pain
progression plus those with both JSL and pain progression; REF -referent.
Table I
Baseline phenotypes and
JSL case status (Primary
phenotypic definition)
Osteoarthritis
andCartilagephenotype (vs. none) was associated with 1.80 (95% CI1.16, 2.79)
times higher odds of experiencing the composite outcome. The
detailed composite outcome results for the primary definitions are
shown in Appendix II.
In sensitivity analyses using the secondary, less stringent defi-
nitions, all phenotypes (vs. none) were associated with an
increased risk of JSL, i.e., inflammation OR 1.72, [95% CI 1.10, 2.67],
bone OR of 1.81 [95% CI 1.14, 2.85], cartilage/meniscus OR 1.99 [95%
CI, 1.27,3.09). Further details regarding JSL as the outcome using the
secondary definition are presented in Table II. Regarding the less
stringent secondary definitions and the composite outcome, the
bone phenotypewas associatedwith increased risk of that outcome
(OR 1.65 [95% CI 1.04, 2.61]). The details of this sensitivity analysis
(secondary definitions, composite outcome) are shown in Appen-
dix III.
In the additional analyses looking at pain only and pain and
structural progression combined as outcomes did not yield signif-
icant associations between phenotype and pain case status. These
results are presented in Appendix IV.Discussion
In this cohort of knees defined by specific structural or clinical
outcomes, the bone phenotype was associated with an increased
odds of having radiographic progression (including those with
radiographic progression only and those with both radiographic
and pain progression), or having both radiographic and painJSL Case OR (95% CI)
No Yes
Inflammatory Phenotype (secondary definition)
No 209 (55%) 174 (45%) REF
Yes 42 (41%) 60 (59%) *1.72 (1.10, 2.67)
Bone Phenotype
No 213 (55%) 177 (45%) REF
Yes 38 (40%) 57 (60%) *1.81 (1.14, 2.85)
Cartilage/meniscus Phenotype (secondary definition)
No 211 (55%) 170 (45%) REF
Yes 40 (38%) 64 (62%) *1.99 (1.27, 3.09)
Number of Phenotypes (secondary analysis)
0 157 (57%) 117 (43%) REF
1 72 (53%) 64 (47%) 1.19 (0.79, 1.80)
2þ 22 (29%) 53 (71%) *3.23 (1.86, 5.61)
Inflammatory Phenotype Group (secondary definition)
No Phenotype 157 (57%) 117 (43%) REF
Inflammatory Phenotype 42 (41%) 60 (59%) *1.92 (1.21, 3.04)
Other Phenotype 52 (48%) 57 (52%) 1.47 (0.94, 2.30)
Bone Phenotype Group (secondary definition)
No Phenotype 157 (57%) 117 (43%) REF
Bone Phenotype 38 (40%) 57 (60%) *2.01 (1.25, 3.24)
Other Phenotype 56 (48%) 60 (52%) 1.44 (0.93, 2.22)
Cartilage/meniscus Phenotype Group (secondary definition)
No Phenotype 157 (57%) 117 (43%) REF
Cart/Meniscus Phenotype 40 (38%) 64 (62%) *2.15 (1.35, 3.41)
Other Phenotype 54 (50%) 53 (50%) 1.32 (0.84, 2.06)
*statistically significant at P < 0.05.
OR eodds ratio; CI econfidence interval; JSL ejoint space loss (i.e., combined JSL
plus composite outcome group, defined as those with JSL only but not pain
progression plus those with both JSL and pain progression; REF ereferent.
Table II
Baseline phenotypes and




F.W. Roemer et al. / Osteoarthritis and Cartilage 28 (2020) 1220e12281224progression together (not including those with only radiographic
progression), whereas the inflammatory phenotype or cartilage/
meniscus phenotype each individually were not significantly
associated with those outcomes. Having any one phenotype (vs.
none) also increased the odds of structural and pain progression
(i.e., the composite outcome), which was likely largely driven by
the bone phenotype given its higher prevalence in this sample. The
sensitivity analysis using a less stringent definition for the inflam-
matory and cartilage/meniscus phenotypes demonstrated that
having two phenotypes more than triples odds for having struc-
tural progression (only), though this latter group was small and
results therefore should be interpreted with caution. Odds for the
predefined outcomes increased for the less stringent definitions.
Together with higher frequencies of specific phenotypes at baseline
using the secondary definitions suggests that these are more useful
to be applied in a clinical trial setting, which will also decrease
potential screen failures.
It has been suggested previously that there is an urgent medical
need to further identify disease phenotypes, preferably by simple
technologies, to allow for patient selection of bone, cartilage and
inflammation-driven OA phenotypes, and then matching the best
intervention to each individual phenotype5,13. From a structural
MRI-centric perspective, we have suggested previously that it is
possible to differentiate five different phenotypes based on the
tissue pathologies that are most severely affected by disease with
two of them, i.e., the atrophic and hypertrophic ones being rare and
of unknown relevance in a clinical trial context14,15. For this reason
we focused on inflammatory, subchondral bone, and cartilage/
meniscus phenotypes only. We clearly acknowledge that this MRI-
based attempt has limitations based on the fact that structural
phenotypes are likely overlapping, and more than one may be
present in an individual14. Further, these phenotypes are based on a
priori hypotheses; whether other relevant structural phenotypes
may exist has not been agnostically evaluated. We also acknowl-
edge that structure is only one aspect that drives progression and
may define an OA phenotype. In a recent meta-analysis on OA
phenotypes Deveza and colleagues found significant heterogeneity
across studies in the selection of participants and characteristics
and methods used to investigate knee OA phenotypes2. Pain
sensitization, psychological distress, radiographic severity, BMI,
muscle strength, inflammation and comorbidities, also play a part
in distinguishing clinically distinct phenotypes. In addition, sex,
obesity and other metabolic abnormalities, the pattern of cartilage
damage, and inflammation may be implicated in delineating
structural knee OA phenotypes. A lack of studies investigating
structural phenotypes has been clearly acknowledged2.
Limitations of our study include the retrospective aspect of our
work analyzing a sample that has been defined by certain outcomes
nested within the larger OAI study6. Future studies will be needed
to identify specific patients with a high likelihood of structural
progression. In addition we excluded knees with posterior medial
root tears as these are commonly considered to be prone to rapid
progression and should not be included in clinical trials11,12. Also
knees without radiographic OA are commonly excluded from
clinical trials. We acknowledge that the matching of cases and
controls has been broken up by those exclusions but we could also
show that KL1 knees and those with posterior root tears were
evenly distributed across the different outcome groups and should
not have biased our analysis. We did not screen the remaining
knees for other diagnoses of exclusion such as subchondral insuf-
ficiency fracture, osteonecrosis, recent trauma or malignant bone
marrow infiltration as we used available MOAKS readings that were
originally performed for the FNIH cohort study. MOAKS does not
include these diagnoses. In addition the overall prevalence of
phenotypes was low, particularly using the stringent definitions,and additional adapted definitions need to be tested regarding rates
of progression and prevalence in a given sample. We have tried this
by introducing a secondary, less stringent definition of phenotypes,
which resulted in a larger proportion of knees fulfilling these cri-
teria.We further also acknowledge that overlap of phenotypes is not
unusual and was observed in 10% of knees using the stringent
definitions and 36% of knees using the secondary, less stringent
definitions. Whether or not patients or knees fulfilling criteria of a
specific phenotype are responsive to a specific therapy or not was
not the focus of the current study. Nonetheless, this work supports
testing of phenotypes for response to therapy as the next step
before considering screening in trials.
The low prevalence of the phenotypes using the primary defi-
nitions, particularly the inflammatory and cartilage/meniscus
phenotypes (prevalence <5%, n < 25), add to the uncertainty
around the estimates of association with progression status and
make it difficult to draw definitive conclusions about the associa-
tions between phenotype and outcome. Future work should eval-
uate these phenotypes in a larger sample or in a cohort with a
higher prevalence of structural deficiencies.
In summary, we demonstrated that the subchondral bone
phenotype was associated with an increased risk of radiographic
progression, or having both radiographic and pain progression
together, whereas the inflammatory phenotype or cartilage/
meniscus phenotype each individually were not associated with
either outcome. The higher frequencies of specific phenotypes us-
ing the secondary definitions suggest that these may be more
useful for application in a clinical trial setting, which will result in
less screen failures. Phenotypic stratification appears to provide
insights into risk for structural or composite structure plus pain
progression, and therefore may be useful to consider when
selecting patients for inclusion in clinical trials.
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0 e None 236 (79%)
1 e Bone only 47 (16%)
1 e Cartilage/meniscus only 6 (2%)
1 e Inflammatory only 2 (1%)
2 e Bone, Cartilage/meniscus 0 (0%)
2 e Bone, Inflammatory 6 (2%)
2 e Cartilage/meniscus, Inflammatory 0 (0%)
3 e All three phenotypes 0 (0%)
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3
177 (94%) 466 (96%)
11 (6%) 19 (4%)
146 (78%) 390 (80%)
42 (22%) 95 (20%)
172 (91%) 463 (95%)
16 (9%) 22 (5%)
126 (67%) 362 (75%)
56 (30%) 111 (23%)
5 (3%) 11 (2%)
1 (1%) 1 (0%)
126 (67%) 362 (75%)
37 (20%) 84 (17%)
11 (6%) 17 (4%)
8 (4%) 10 (2%)
3 (2%) 3 (1%)
1 (1%) 7 (1%)
1 (1%) 1 (0%)
1 (1%) 1 (0%)
KL 2 þ 3 combined
3
142 (76%) 383 (79%)
46 (24%) 102 (21%)
146 (78%) 390 (80%)
42 (22%) 95 (20%)
99 (53%) 381 (79%)
89 (47%) 104 (21%)
73 (39%) 274 (56%)
67 (36%) 136 (28%)
34 (18%) 60 (12%)
14 (7%) 15 (3%)
73 (39%) 274 (56%)
10 (5%) 44 (9%)
44 (23%) 50 (10%)
13 (7%) 42 (9%)
(continued on next page)
(continued )
KL Grade and Secondary Phenotype Definition
KLG KL 2 þ 3 combined
2 3
2 e Bone, Cartilage/meniscus 0 (0%) 15 (8%) 15 (3%)
2 e Bone, Inflammatory 18 (6%) 3 (2%) 21 (4%)
2 e Cartilage/meniscus, Inflammatory 8 (3%) 16 (9%) 24 (5%)
3 e All three phenotypes 1 (0%) 14 (7%) 15 (3%)
KellgreneLawrence grades and distribution of phenotypes (primary and secondary definitions) OsteoarthritisandCartilage
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No Yes
Inflammatory Phenotype
Age 61.5 (8.7) 61.1 (10.4)
BMI 31.0 (4.8) 30.6 (4.6)
Gender
Male 190 (41%) 7 (37%)
Female 276 (59%) 12 (63%)
Bone Phenotype
Age 61.7 (8.9) 60.4 (8.6)
BMI 30.8 (4.7) 31.9 (5.2)
Gender
Male 161 (41%) 36 (38%)
Female 229 (59%) 59 (62%)
Cartilage/Meniscus Phenotype
Age 61.4 (8.7) 62.3 (10.3)
BMI 31.0 (4.8) 31.5 (5.1)
Gender
Male 184 (40%) 13 (59%)
Female 279 (60%) 9 (41%)
Inflammatory Phenotype (Secondary Definition)
Age 61.5 (8.5) 61.2 (9.8)
BMI 31.0 (4.8) 31.0 (4.8)
Gender
Male 148 (39%) 49 (48%)
Female 235 (61%) 53 (52%)
Cartilage/Meniscus Phenotype (Secondary Definition)
Age 61.2 (8.7) 62.3 (9.1)
BMI 31.1 (4.8) 30.8 (4.8)
Gender
Male 130 (34%) 67 (64%)
Female 251 (66%) 37 (36%)











No 318 (68%) 148 (32%) REF
Yes 12 (63%) 7 (37%) 1.25 (0.48, 3.25)
Bone Phenotype
No 274 (70%) 116 (30%) REF
Yes 56 (59%) 39 (41%) *1.65 (1.04, 2.61)
Cartilage/meniscus Phenotype
No 315 (68%) 148 (32%) REF
Yes 15 (68%) 7 (32%) 0.99 (0.40, 2.49)
Number of Phenotypes
0 257 (71%) 105 (29%) REF
1 64 (58%) 47 (42%) *1.80 (1.16, 2.79)
2þ 9 (75%) 3 (25%) 0.82 (0.22, 3.07)
Inflammatory Phenotype Group
No Phenotype 257 (71%) 105 (29%) REF
Inflammatory Phenotype 12 (63%) 7 (37%) 1.43 (0.55, 3.73)
Other Phenotype 61 (59%) 43 (41%) *1.73 (1.10, 2.71)
Bone Phenotype Group
No Phenotype 257 (71%) 105 (29%) REF
Bone Phenotype 56 (59%) 39 (41%) *1.70 (1.07, 2.72)
Other Phenotype 17 (61%) 11 (39%) 1.58 (0.72, 3.50)
Cartilage/meniscus Phenotype Group
No Phenotype 257 (71%) 105 (29%) REF
Cartilage/Meniscus Phenotype 15 (68%) 7 (32%) 1.14 (0.45, 2.88)
Other Phenotype 58 (57%) 43 (43%) *1.81 (1.15, 2.86)
*statistically significant at P < 0.05.










Inflammatory Phenotype (secondary definition)
No 265 (69%) 118 (31%) REF
Yes 65 (64%) 37 (36%) 1.28 (0.81, 2.02)
Bone Phenotype
No 274 (70%) 116 (30%) REF
Yes 56 (59%) 39 (41%) *1.65 (1.04, 2.61)
Cartilage/meniscus Phenotype (secondary definition)
No 264 (69%) 117 (31%) REF
Yes 66 (63%) 38 (37%) 1.30 (0.82, 2.05)
Number of Phenotypes (secondary definition)
0 193 (70%) 81 (30%) REF
1 95 (70%) 41 (30%) 1.03 (0.66, 1.61)
2þ 42 (56%) 33 (44%) *1.87 (1.11, 3.16)
Inflammatory Phenotype Group (secondary definition)
No Phenotype 193 (70%) 81 (30%) REF
Inflammatory Phenotype 65 (64%) 37 (36%) 1.36 (0.84, 2.19)
Other Phenotype 72 (66%) 37 (34%) 1.22 (0.76, 1.97)
Bone Phenotype Group (secondary definition)
No Phenotype 193 (70%) 81 (30%) REF
Bone Phenotype 56 (59%) 39 (41%) 1.66 (1.02, 2.69)
Other Phenotype 81 (70%) 35 (30%) 1.03 (0.64, 1.65)
Cartilage/meniscus Phenotype Group (secondary definition)
No Phenotype 193 (70%) 81 (30%) REF
Cartilage/meniscus Phenotype 66 (63%) 38 (37%) 1.37 (0.85, 2.21)
Other Phenotype 71 (66%) 36 (34%) 1.21 (0.75, 1.95)
*statistically significant at P < 0.05.





andCartilageAppendix IVaPain Case* OR (95% CI)
No Yes
Inflammatory Phenotype
No 232 (50%) 234 (50%) REF
Yes 8 (42%) 11 (58%) 1.36 (0.54, 3.45)
Bone Phenotype
No 199 (51%) 191 (49%) REF
Yes 41 (43%) 54 (57%) 1.37 (0.87, 2.16)
Cartilage/meniscus Phenotype
No 227 (49%) 236 (51%) REF
Yes 13 (59%) 9 (41%) 0.67 (0.28, 1.59)
Number of Phenotypes
0 184 (51%) 178 (49%) REF
1 50 (45%) 61 (55%) 1.26 (0.82, 1.93)
2þ 6 (50%) 6 (50%) 1.03 (0.33, 3.27)
Inflammatory Phenotype Group
No Phenotype 184 (51%) 178 (49%) REF
Inflammatory Phenotype 8 (42%) 11 (58%) 1.42 (0.56, 3.62)
Other Phenotype 48 (46%) 56 (54%) 1.21 (0.78, 1.87)
Bone Phenotype Group
No Phenotype 184 (51%) 178 (49%) REF
Bone Phenotype 41 (43%) 54 (57%) 1.36 (0.86, 2.15)
Other Phenotype 15 (54%) 13 (46%) 0.90 (0.41, 1.94)
Cartilage/meniscus Phenotype Group
No Phenotype 184 (51%) 178 (49%) REF
Cartilage/meniscus Phenotype 13 (59%) 9 (41%) 0.72 (0.30, 1.72)
Other Phenotype 43 (43%) 58 (57%) 1.39 (0.89, 2.18)
* pain only and pain and structural progression combined.
OR eodds ratio; CI econfidence interval; REF -referent.
Baseline phenotypes and
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No Yes
Inflammatory Phenotype (secondary definition)
No 191 (50%) 192 (50%) REF
Yes 49 (48%) 53 (52%) 1.08 (0.70, 1.67)
Bone Phenotype
No 199 (51%) 191 (49%) REF
Yes 41 (43%) 54 (57%) 1.37 (0.87, 2.16)
Cartilage/meniscus Phenotype (secondary definition)
No 183 (48%) 198 (52%) REF
Yes 57 (55%) 47 (45%) 0.76 (0.49, 1.18)
Number of Phenotypes (secondary analysis)
0 135 (49%) 139 (51%) REF
1 68 (50%) 68 (50%) 0.97 (0.64, 1.47)
2þ 37 (49%) 38 (51%) 1.00 (0.60, 1.66)
Inflammatory Phenotype Group (secondary definition)
No Phenotype 135 (49%) 139 (51%) REF
Inflammatory Pheno 49 (48%) 53 (52%) 1.05 (0.67, 1.66)
Other Phenotype 56 (51%) 53 (49%) 0.92 (0.59, 1.43)
Bone Phenotype Group (secondary definition)
No Phenotype 135 (49%) 139 (51%) REF
Bone Phenotype 41 (43%) 54 (57%) 1.28 (0.80, 2.05)
Other Phenotype 64 (55%) 52 (45%) 0.79 (0.51, 1.22)
Cartilage/meniscus Phenotype Group (secondary definition)
No Phenotype 135 (49%) 139 (51%) REF
Cart/Meniscus Phenotype 57 (55%) 47 (45%) 0.80 (0.51, 1.26)
Other Phenotype 48 (45%) 59 (55%) 1.19 (0.76, 1.87)
* pain only and pain and structural progression combined.
OR eodds ratio; CI econfidence interval; REF -referent.
Baseline phenotypes and
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